Functional effect of the Hsa-miR-185* on the <i>TrkB-T1</i> 3′UTR sequence in HEK 293 cell line. by Gilles Maussion (156014)

“…<p>A: Schematic representation of <i>TrkB-T1</i> 3′UTR sequence including the five putative binding sites for Hsa-miR-185*. …”

Effects of tesofensine and phentermine on locomotion, quiet-awake/sleep, and head weaving stereotypy in rats. by Claudia I. Perez (7824965)

“…Note that for phentermine, the onset of stereotypy decreases across days. E. For the first two days, the variables locomotion, quiet awake/sleep, onset, and stereotypy were analyzed using a clustering algorithm (t-SNE). …”

Relative abundance of bacterial families, for which statistically significant differences between the cohorts of IBS patients and healthy individuals (GreenGenes nomenclature). by V. Ivashkin (10960750)

Impact of precipitation and temperature changes on hydrological responses of small-scale catchments in the Ethiopian Highlands by Tatenda Lemann (3187935)

Comparison of 1D and 3D reservoir heat transport models and temperature effects on mass transport by Bruna Arcie Polli (10356390)

CFD simulation of cannabidiol delivery through microneedle patches by Liqun Shi (8309856)

Dirt on photovoltaic modules and efficient energy generation in the Brazilian semiarid by Tiago L. S. de Souza (12820142)

BIOCHEMICAL AND PIGMENT ANALYSIS ON PHYCOREMEDIATED MICROALGAL BIOMASS by G. k. Saravanan (515483)

Temperature influence on mobility and charge density model of photovoltaic cells by J.S.T. Souza (6380096)

Supplementary Material for: Cerebral Hemodynamic Failure Presenting as Limb-Shaking Transient Ischemic Attacks by Nedelmann M. (4127125)

Unexpected transient phenomena in positive lightning by Ziqin Ding (8470035)

Rhinorrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Vomit-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Table_1_Impact of the COVID-19 Lockdown on Air Quality and Resulting Public Health Benefits in the Mexico City Metropolitan Area.DOCX by Iván Y. Hernández-Paniagua (10430552)

“…SO₂ decreased only during Phase 3 in a near-road environment. …”

Symptoms free-days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Respiratory symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Other symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Diarrhea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Gastrointestinal symptoms-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”

Nausea-free days up to day 10. by Bruno Martins Tomazini (6509528)

“…<div><p>Background</p><p>Halofuginone (PJS-539) is an oral prolyl-tRNA synthetase inhibitor that has a potent <i>in vitro</i> activity against SARS-CoV-2 virus. …”